Madrigal Pharmaceuticals, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-2.34 | — | — | Miss |
| Q12026 FY2026 | $-3.61 | $-3.25 | +10.0% | Beat |
| 2026-02-19 | $0.04 | — | — | Miss |
Back to MDGL overview · MDGL holders · MDGL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.